Riskpilot← Back to searchSign inGet full accessANDEBU APOTEK AS
ASActiveOrg 993328774Andebu Sentrum 24, 3158 AndebuRetail sale of pharmaceutical products · NACE 4773Est. 20080 employeeswww.andebuapotek.no
Revenue 2024
NOK 28,6M
+3% vs 2023
EBITDA margin
2.3%
-28% vs 2023
Equity ratio
-3.9%
Financial strength
Net profit 2024
NOK 242K
-38% vs 2023
| Revenue | NOK 28,6M | +3% |
| EBITDA | NOK 670K | -28% |
| Net profit | NOK 242K | -38% |
| Total assets | NOK 4,4M | -43% |
| Equity | NOK -173K | +58% |
| Employees | 0 | — |
Legal name
ANDEBU APOTEK AS
Org number
993328774
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
24. november 2008
Share capital
NOK 200 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene eller daglig leder alene.
Company purpose
Apotekvirksomhet.
Address
Andebu Sentrum 24, 3158 Andebu
Website
www.andebuapotek.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 23 870 | 26 818 | 26 320 | 27 777 | 28 578 |
| Staff expenses | −4 593 | −4 873 | −4 831 | −4 585 | −5 005 |
| EBITDA | 297 | 692 | 468 | 934 | 670 |
| Depreciation & amort. | −92 | −100 | −346 | −332 | −290 |
| EBIT | 206 | 591 | 122 | 602 | 380 |
| Net financials | −82 | −75 | −105 | −104 | −69 |
| Profit before tax | 124 | 516 | 17 | 498 | 311 |
| Tax | 27 | 113 | 4 | 109 | 68 |
| Net profit | 97 | 402 | 13 | 388 | 242 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5 315 | 5 445 | 5 517 | 7 780 | 4 401 |
| Equity | −1 836 | −1 157 | −803 | −415 | −173 |
| Long-term debt | 1 498 | 356 | 0 | 2 050 | 0 |
| Short-term debt | 5 653 | 6 245 | 6 321 | 6 145 | 4 573 |
| Total debt | 7 151 | 6 601 | 6 321 | 8 195 | 4 573 |
EBITDA margin
2.3%
This company
15.8%
Market median
-85% vs market
20202024
Equity ratio
-3.9%
This company
38.2%
Market median
-110% vs market
20202024
Return on equity
24245600.0%
This company
18.4%
Market median
+131769465% vs market
20202024
Net profit margin
0.8%
This company
8.1%
Market median
-90% vs market
20202024
Asset turnover
6.49×
This company
1.12×
Market median
+479% vs market
20202024
Debt / equity
26.50×
This company
0.62×
Market median
-4174% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SM Chief Executive Officer | Chief Executive Officer | 2022 |
GO Deputy Member | Deputy Member | 2008 |
| Former (1) | ||
KA Chief Executive Officer | Chief Executive Officer | 2010 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2008 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Gokstadapotekene As
ANDEBU APOTEK AS Board members of ANDEBU APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Slawomir Mazur | Chief Executive Officer | 0 companies |
| Katarzyna Agata Gripsrud | Chief Executive Officer | 0 companies |
| Garm Oscar Lyckander | Deputy Member | 0 companies |
| Bror-Lennart Mentzoni | Chairman | 0 companies |